Melkart Duo

Metformin Hydrochloride and Vildagliptin, the active ingredients in Melkart Duo, are a Biguanide and a DPP‑4 inhibitor presented as an oral tablet for oral use. They are indicated for the management of type 2 diabetes mellitus in adults. GNH USA supplies Melkart Duo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Melkart Duo is an oral antidiabetic combination that targets hyperglycaemia in type 2 diabetes. - Type 2 diabetes mellitus: improves glycaemic control when used with diet and exercise. - Inadequate control on metformin alone: provides additional glucose‑lowering effect as adjunct therapy. - Combination with other antidiabetics: can be co‑prescribed with insulin or sulfonylureas to achieve target HbA1c.

Common side effects are generally mild and related to the gastrointestinal system or central nervous system.

Common Side Effects: - Nausea: transient feeling of stomach upset. - Diarrhoea: loose stools, often mild. - Abdominal discomfort: cramping or pain. - Headache: mild to moderate intensity. - Dizziness: occasional light‑headedness. - Upper respiratory tract infection: mild cold‑like symptoms.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: inflammation of the pancreas. - Hepatic dysfunction: abnormal liver enzymes. - Allergic reactions: rash, pruritus, or angio‑edema. - Stevens‑Johnson syndrome: severe skin reaction.

Before initiating therapy, clinicians should assess patient‑specific factors and monitor for adverse events. - Renal function assessment: evaluate kidney function before starting and periodically thereafter. - Hepatic impairment: use with caution in patients with liver disease. - Risk of hypoglycaemia: monitor blood glucose when combined with insulin or sulfonylureas. - Lactic acidosis warning: discontinue if signs such as muscle pain or rapid breathing appear. - Pregnancy and lactation: avoid unless benefits outweigh potential risks. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Melkart Duo may interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of severe hypoglycaemia. - Iodinated contrast agents: may impair renal function and raise metformin levels. - Strong CYP2C9 inhibitors: can affect vildagliptin metabolism. - Alcohol abuse: heightens risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Diuretics: may alter renal clearance of metformin. - Beta‑blockers: can mask symptoms of hypoglycaemia. - ACE inhibitors or ARBs: monitor renal function and electrolytes. - Rifampicin: may reduce plasma concentrations of vildagliptin.